Furthermore, there is now an extension trial for up to 5 years to study the safety and tolerability of continued setmelanotide in patients with obesity associated with genetic defects upstream of the MC4R in the leptin–melanocortin pathway.80 The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.